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Hydrolysis of Escherichia coli membrane phospholipids by pancreatic phospholipase A 2 was inhibited by 
lipocortin from human monocytes in a substrate dependent manner. Inhibition was completely overcome 
at substrate concentrations above 250 pM. Lipocortin also inhibited partially purified preparations of two 
intracellular phospholipases A 2 isolated from rat liver mitochondria and rat platelets when these enzymes 
were assayed at low micromolar concentrations of phosphatidylethanolamine. Inhibition gradually de- 
creased with increasing substrate concentrations both for pancreatic and platelet phospholipase A 2 and be- 
came completely abolished above 15 and 50/tM phosphatidylethanolamine, respectively. 
Lipocortin; Phospholipase .4.2; Phosphatidylethanolamine 
1. INTRODUCTION 
Lipocortins belong to a family of proteins 
described initially as induced by glucocor- 
ticosteroids and able to inhibit phospholipase A2 
(see [1-4]). Since their initial description, they 
have been cloned and sequenced [5-7] and have 
been related to a family of calcium and 
phospholipid binding proteins, namely calpactins 
and calelectrins. Indeed, lipocortin I is identical to 
calpactin II, and lipocortin II identical to the heavy 
chain of calpactin I, both membrane cytoskeletal 
proteins, able to bind calcium, phospholipid and 
actin [8-10]. Calelectrin was initially described in 
the electric organ of Torpedo marmorata nd later 
in mammalian tissues, as a protein able to bind 
calcium and chromaffin granule membranes, and 
was considered as a candidate for Ca 2+ dependent 
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regulators of membrane events [11-13]. The 
lipocortins, the calpactins and the calelectrins all 
possess a 17 amino acid residue consensus se- 
quence [14-16]. 
The way lipocortins and related proteins inhibit 
phospholipase A2 is still a matter of debate. Initial- 
ly, a direct inhibition by protein-protein i terac- 
tion was implicated [17] although inhibition of 
bacterial phospholipase C and plant phospholipase 
D in vitro by lipomodulin, a former name for 
lipocortin [17], challenged such a specific protein- 
phospholipase A2 interaction. The recent recogni- 
tion that lipocortins are able to bind to 
phospholipids, the substrates for phospholipase 
A2, suggested possibilities for alternative modes of 
actions. In addition, phospholipase A2 inhibition 
by lipocortins from various sources has generally 
been assayed by using porcine pancreatic 
phospholipase A2 and either highly labeled 
Escherichia coli membranes [5-7,18] or 
phosphatidylcholines [17,19], both at very low 
substrate concentrations in the micromolar ange. 
Indeed a recent paper by Davidson et al. [20] 
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demonstrated that phospholipase A2 inhibition by 
calpactins isolated from bovine lung was substrate 
dependent. While 100% inhibition was observed at 
2/tM E. coli-derived phospholipid vesicles, no in- 
hibition was found with this substrate above 8/zM. 
However, inhibition was only studied for the ex- 
tracellular phospholipase A2 from porcine pan- 
creas. In this paper, we studied the effect of human 
lipocortins on this enzyme as well as on two par- 
tially purified preparations of intracellular 
phospholipases Az obtained from rat liver 
mitochondria nd rat platelets. 
2. MATERIALS AND METHODS 
[3H]Oleic acid (4.2 Ci/mmol) was purchased 
from Amersham, Paris; fatty acid free bovine 
serum albumin (BSA) was from Sigma, St. Louis, 
MO; and porcine pancreatic phospholipase A2 (700 
Units/rag) from Boehringer, Mannheim. 
2.1. Isolation of proteins 
2.1.1. Lipocortin 
Lipocortin (32 kDa) was isolated from 
peripheral mononuclear cells as described in the 
accompanying paper [27]. The proteins were 
characterized by their migration in gel elec- 
trophoresis, by their isoelectric point and by 
Western blotting using a monoclonal antibody 
raised against rat renal lipocortin and a polyclonal 
anti-32-kDa ntibody. 
2.1.2. Platelet phospholipase A2 
Rat platelet phospholipase A2 was partially 
purified from platelet extracts prepared as de- 
scribed [21]. Briefly, platelet lysates were extracted 
for 1 h at 4°C with a buffer containing 25 mM 
Tris-HC1 (pH 7.4) and 1 M KCI. After centrifuga- 
tion for 1 h at 100000 × g, the clear supernatant 
containing over 85°70 of the platelet phospholipase 
A2 activity, was chromatographed over a 
Sepharose 4B column to which a monoclonal an- 
tibody against rat liver mitochondrial 
phospholipase A2 had been coupled. As shown [22] 
this monoclonal antibody cross-reacted with rat 
platelet phospholipase Az. After more than 95°70 of 
the applied proteins had been eluted with the ap- 
plication buffer, phospholipase A2 activity was 
eluted with a glycine buffer (pH 2.5) in yields of 
150-200°70. The high yields are probably due to the 
removal of inhibiting compounds present in the 
platelet extract [22]. Details of this purification 
will be published elsewhere. The amount of protein 
in the final preparation was too low to allow for an 
accurate determination. 
2.1.3. Liver mitochondrial phospholipase A2 
Rat liver mitochondrial phospholipase A2 was 
purified as described [22] by AcA 54 
chromatography of delipidated mitochondrial ex- 
tracts. The specific activity of this preparation 
amounted to 350 nmol -min- l .mg protein -1. 
2.2. Assay of porcine pancreatic phospholipase A2 
using E. coli membranes 
The phospholipase Az inhibitory assay was per- 
formed using [3H]oleic acid-labeled E. coil mem- 
branes as described in [18]. The proteins were 
preincubated for 10 min with 100 ng of porcine 
pancreatic phospholipase A2 in a final volume of 
350/A with 100 mM Tris-HCl, pH 8.0, 10 mM 
Ca 2+, at 4°C. Autoclaved [3H]oleic acid-labeled, 
whole E. coli membranes were added as substrate 
to initiate the reaction which was terminated 
10 min later by adding 100/A of 2N HC1. 100/zl of 
fatty acid free BSA (100 mg/ml) was then added, 
the tubes were vortexed and centrifuged 5 min at 
10000 × g. 200/zl of the supernatant containing 
released [3H]oleic acid was counted by liquid scin- 
tillation spectrometry. Results were expressed as 
percentage inhibition of released oleic acid in the 
presence or absence of the proteins to be tested 
minus blanks where phospholipase A2 and the in- 
hibitory proteins were omitted. 
2.3. Assay of antiphospholipase A2 activity using 
Phosphatidylethanolamine substrate 
Phospholipases were preincubated for 10 min 
with the indicated amount of lipocortin and 
10 mM Ca 2÷ in 100 mM Tris-HCl, pH 8.5, at 4°C 
prior to addition of 1-acyl-2-[1-14C]linoleoyl- 
phosphatidylethanolamine. Substrate concentra- 
tions and specific radioactivities were variable as 
specified in the figure legends. After 30 rain in- 
cubation at 37°C, released [14C]linoleate was 
determined by a modified Dole extraction pro- 
cedure as described in [21]. All experiments, in- 
cluding blanks containing neither enzymes nor 
lipocortin, were carried out in duplicate. 
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2.4. Phospholipid measurement 
Phospholipids were extracted according to the 
procedure described by Bligh and Dyer [23]. After 
evaporation under nitrogen, the phosphate content 
was measured according to Bfttcher et al. [24]. 
2.5. Protein measurement 
Proteins were measured as described by Lowry 
et al. [25]. 
3. RESULTS AND DISCUSSION 
Fig.1 shows the effect of increasing concentra- 
tions of [~H]oleate-labeled E. coli membranes on 
the inhibition of pancreatic phospholipase A2 by 
lipocortin from human monocytes. At a mem- 
brane concentration equivalent to 15/zM 
phospholipid the enzyme was inhibited for 72°7o by 
2.5/zg lipocortin. This inhibition gradually 
decreased with increasing substrate concentration 
until at 250/zM substrate, the inhibition was com- 
pletely abolished. These results are in good agree- 
ment with the recent data of Davidson et al. [20]. 
When using the same enzyme and phospholipid 
substrate in the form of whole E. coli cells these 
authors noted that inhibition by bovine lung 
calpactins ceased above 200/zM phospholipid. To 
see whether or not this phenomenon was specific 
for the extracellular pancreatic phospholipase A2 
in combination with the negatively charged E. coli 
phospholipids, we investigated the effect of 
lipocortin on two intracellular phospholipases A2 
using the neutral phosphatidylethanolamine as 
substrate. 
Initial experiments in this series indicated that 
at a substrate concentration of 200/zM 1-a- 
cyl- 2- [1 - 14C]linoleoylphosphatidylethanolamine, 
neither pancreatic phospholipase A2 (4 ng) nor rat 
liver mitochondrial phospholipase A2 (20 ng, 
based on a spec. act. of 8 Units/mg [26]) were in- 
hibited by the 32-kDa lipocortin up to amounts of 
7.5/zg. However, when the substrate concentration 
was reduced to 2/zM, the same amounts of pan- 
creatic and mitochondrial enzyme were inhibited 
80070 and 42o70, respectively, by 7.5/zg lipocortin. 
Under similar conditions, an amount of rat platelet 
phospholipase A2 releasing 0.43 nmol of linoleate 
was inhibited 56o7o. The inhibition of rat platelet 
phospholipase A2 at low substrate concentrations 
is dose-dependent (fig.2). This inhibition reaches a
plateau at 75o7o for 3/tg of the 32-kDa lipocortin. 
This could indicate that either the enzyme- 
lipocortin complex has some residual activity or 
that the phosphatidylethanolamine-lipocortin 
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Fig.l. Effect of E. coli membrane substrate 
concentration o  inhibition of pancreatic phospholipase 
A2 by lipocortin. The incubations contained 0.1/zg 
phospholipase A2 and variable amounts of [3H]oleate- 
labeled E. coli membranes quivalent with the.indicated 
concentrations of phospholipids in the absence or 
presence of 2.5/zg of the 32-kDa lipocortin from human 
monocytes. 
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Fig.2. Dose response of lipocortin on rat platelet 
phospholipase A2 inhibition. Incubations contained 
5.0/zM 1 -acyl-2- [ l-~4C]linoleoyllphosphatidylethanol - 
amine (spec. act. 4000 dpm/nmol) and a constant 
amount of platelet phospholipase A2 in the absence or 
presence of the indicated amounts of lipocortin. In the 
absence of lipocortin, the enzyme released 0.36 nmol 
linoleate. 
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complex is still a substrate for the platelet 
phospholipase A/, though inferior compared to 
phosphatidylethanolamine alone. In the former 
case, if lipocortin interacted solely with the en- 
zyme, one would expect he lipocortin inhibition of 
the phospholipase A2 tO be independent of the 
substrate concentration. On the other hand, if 
lipocortin exerted its effects by binding to 
substrate or if the enzyme-lipocortin complex 
dissociated in the presence of phospholipid and 
Ca 2+, one would expect the phospholipase A2 in- 
hibition to decrease with increasing substrate con- 
centration. In agreement with fig.l, the latter 
phenomenon is also seen with phosphatidyl- 
ethanolamine as substrate, both for rat platelet 
and porcine pancreatic phospholipase A2 (fig.3). 
However lipocortin inhibition of platelet phos- 
pholipase A2 appears omewhat less sensitive to in- 
creasing phosphatidylethanolamine concentrations 
than observed for pancreatic phospholipase A2. 
In summary, the data have shown that inhibition 
of the extracellular pancreatic phospholipase A2 by 
human monocyte lipocortin is dependent on the 
amount of E. coli membrane substrate in a manner 
corroborating recently published experiments us- 
ing a similar assay system and bovine lung calpac- 
tins. In addition, we have shown that two 
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Fig.3. Effect of phosphatidylethanolamine concen- 
tration on phospholipase A2 inhibition by lipocortin. 
Substrate (as in fig.2) concentration was varied as 
indicated both in the absence or presence of 3/zg 
lipocortin. (~----0) Pancreatic phospholipase A2 (4 ng); 
(t3-----o) an amount of rat platelet phospholipase A2 
releasing 0.16 nmol and 1.5 nmol of linoleate at 2/zM 
and 40/zM substrate, respectively. 
phospholipases A2 from intracellular origin, i.e. 
rat liver mitochondria nd rat platelets are likewise 
inhibited by lipocortin at low concentrations of a 
neutral phospholipid substrate. However, also in 
these cases, lipocortin inhibition of phospholipase 
A2 activity is completely abolished at substrate 
concentrations above 50/zM. At present it cannot 
be decided whether this relief of inhibition is 
caused by direct lipocortin-phospholipid interac- 
tions that have been described recently [8-10] 
or to dissociation of inactive phospholipase 
A/-lipocortin complexes in the presence of 
phospholipids. Whatever the detailed molecular 
mechanism, it is clear, however, that these results 
have important implications for the proposed 
functions of lipocortins as regulators of in- 
tracellular phospholipase A2 activity in response to 
glucocorticosteroid treatment of cells. 
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